Home » Business News » 2013 » March » March 26, 2013


March 26, 2013 - London

GHENT, Belgium, 26 March 2013 - Ablynx [Euronext Brussels: ABLX] today announced that its 2013 Annual and Extraordinary General meeting (AGM) will be held on Thursday, 25 April 2013 at 11:00h CET at its headquarters at Technologiepark 21, 9052 Ghent.

The convocation and proxy statement, agenda, and annual accounts 2012 will be directly and permanently available on the Company's website at from 26 March 2013.

The most important resolutions included in the agenda relate to the annual accounts 2012, the renewal of the authorised capital and the composition of the Board of Directors including the resignation of two non-executive Directors: Dr Roger Perlmutter who, to avoid conflicts of interest, is resigning from the Ablynx Board following his recent appointment at Merck & Co. as Executive Vice President and President of Merck Research Laboratories, and Geert Cauwenbergh who after five years will retire from the Ablynx Board.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on

For more information, please contact

Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
   +32 (0)473 39 50 68

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330

press release in pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE



Comment on this story